Corvus insider Miller reports 7.8% CRVS stake
Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing. As of December 31, 2025, Dr. Richard A. Miller is reported as the beneficial owner of 6,085,922 shares of common stock, or 7.8% of the class, based on 74,681,872 shares outstanding as of November 4, 2025.
Dr. Miller’s position includes 1,136,707 shares held directly, 1,188,103 shares held through the Miller-Horning Family Trust, and 3,761,112 shares underlying stock options that are vested or vest within 60 days of December 31, 2025. The Miller-Horning Family Trust and Dr. Sandra J. Horning each beneficially own 1,188,103 shares, representing 1.6% of the common stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Corvus Pharmaceuticals (CRVS) is held by the Miller-Horning Family Trust?
What is Sandra J. Horning’s ownership stake in Corvus Pharmaceuticals (CRVS)?
How were the ownership percentages for CRVS calculated in this Schedule 13G/A?
What portion of Richard A. Miller’s CRVS stake consists of stock options?
Does this Corvus Pharmaceuticals (CRVS) Schedule 13G/A indicate group ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.